New coalition formed to fight heart disease across Asia
On June 25, 2023, patient organizations, allied health professionals, academia, corporate partners, and a global health think-tank came together to launch the Asia-Pacific Cardiovascular Disease Alliance (APAC CVD Alliance), a multisectoral coalition committed to improving heart health and reducing the CVD burden across nine health systems in Asia – Australia, China, India, Indonesia, Japan, Malaysia, South Korea, Thailand, and Vietnam. Based in Singapore as its regional hub for Southeast Asia, global health think-tank ACCESS Health International is the secretariat for the APAC CVD Alliance.
CVD is the leading cause of death in the Asia-Pacific, with the largest increase in premature deaths occurring in East Asia, South Asia, and Southeast Asia over the last 20 years. In 2019 alone, over 10 million people died of heart disease in Asia, making up 35% of all deaths in the region.
With four strategic partners – the Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB), Global Alliance for Patient Access (GAfPA), Global Heart Hub (GHH), Universiti Teknologi MARA (UiTM) Faculty of Medicine in Malaysia – and corporate partners Amgen, Novartis, and Roche Diagnostics, the APAC CVD Alliance aims to:
- Increase public and policy awareness of the importance of tackling CVD at regional and domestic forums in Asia;
- Encourage implementation of scalable and sustainable CVD innovations across all health systems, and
- Emphasize that fighting CVD is a much-needed investment for healthy societies and productive economies.
Growing affluence, rapid urbanization, and aging populations in Asia present health systems with an increasing burden of CVD’s direct and indirect costs and poor health outcomes.
“Accurate and rapid diagnoses for people with CVD are fundamental to all health systems”, said Dr Tony Badrick, President, APFCB. “As the largest clinical biochemistry and laboratory federation in Asia, we have seen that investing in capacity building and education of laboratory professionals are essential for early detection and treatment of CVD and other non-communicable diseases. The APAC CVD Alliance’s mandate to elevate policy awareness dovetails with the APFCB’s goal of encouraging continual improvements to laboratory practices in the region.”
“To tackle the rise of CVD in the region, we first have to confront the barriers that prevent patients from accessing quality cardiac management in their healthcare systems. Together with our alliance partners, Amgen aims to unify multi-sectorial efforts towards the common goal of recognizing and overcoming these challenges. Success for us means creating sustainable solutions that provide more effective, longer term care for patients in the region”, said My Linh Kha, Senior Vice President and General Manager, Amgen Japan and Asia Pacific.
The APAC CVD Alliance will adopt a patient-centered approach across the entire CVD care continuum – prevention; early detection; treatment, cardiac rehabilitation, and step-down care.
Brian Kennedy, Executive Director, GAfPA said, “We are proud to partner the APAC CVD Alliance to advance patient engagement with clinicians and healthcare providers in the Asia-Pacific. With diverse stakeholders, we can ensure that patients’ voices are heard and that policies are developed with the patient at the center.”
“We are excited to join the APAC CVD Alliance to provide a global voice for those affected by CVD in Asia”, added Neil Johnson, Executive Director, GHH. “As a long-time heart patient advocate, I believe we can make a real difference for patients and their families by partnering professionals and policymakers in Asia.”
“According to the World Heart Federation, 80% of cardiovascular disease, including heart disease and stroke, is preventable. This is a shocking reality and calls for urgent action”, said Iris Zemzoum, President, Novartis Asia Pacific, Middle East and Africa. “At Novartis, we envision a world where CVD is eliminated so patients can live longer and healthier lives. This alliance is a powerful example of forging sustainable partnerships across the healthcare ecosystem and working together to find innovative ways to unblock the barriers that stand in the way of heart health.”
Building interdisciplinary, multisectoral partnerships are essential to unite CVD action across borders, especially with diverse socio-economic and cultural contexts in Asia.
“CVD control cannot be accomplished with clinicians alone”, said Associate Professor Dr Fazah Akhtar Hanapiah, Dean, Faculty of Medicine, UiTM. “The faculty has been working tirelessly in co-creating innovative solutions that bring together multidisciplinary healthcare professionals and other partners along the care continuum to prevent, treat, educate, and empower those living with CVD. Our academic, clinical and research background gives us that different edge in tackling the CVD crisis. We are excited to join the APAC CVD Alliance as a strategic partner, to improve patient well-being and care.”
“A healthier, equitable future requires a renewed focus on chronic disease management and a willingness to look beyond physical symptoms. Chronic conditions such as heart disease come at a high personal cost to the person living with it, their families and communities. The Alliance provides an excellent platform to raise awareness around heart health. More importantly, it creates a collective opportunity to bring multiple voices that are critical to driving better healthcare for patients, lowering cost to society and creating a national push for greater access to cardiovascular disease innovations”, said Lance Little, Head of Region, Asia Pacific, Roche Diagnostics Asia Pacific
ACCESS Health International (Asia) President Dr Krishna Reddy said, “The Alliance aims to harness the existing good work in tackling CVD in the Asia-Pacific. ACCESS Health is proud to be the secretariat for this regional initiative and we look forward to improving investment in CVD innovations in policies, care models, products, or services across all health systems.”
We are keen to work with more patients in Asia. We’d love to have a chat.
The Alliance is made possible with the support of Amgen, Novartis, and Roche Diagnostics. Read our commitment to transparency.